VERA Stock Overview
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Vera Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.65 |
| 52 Week High | US$50.78 |
| 52 Week Low | US$6.07 |
| Beta | 1.05 |
| 1 Month Change | -9.54% |
| 3 Month Change | 31.38% |
| 1 Year Change | 496.24% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 244.78% |
Recent News & Updates
Recent updates
Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect
Jan 25Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove
Sep 06Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17
Aug 10Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth
Feb 16
Vera: Biotech With 3 Mid-Stage Programs With Potential For Success
Jan 19Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot
Jan 07We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth
Oct 25Vera Therapeutics soars 16% on three new favorable view from analysts
Jun 08Shareholder Returns
| VERA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.3% | -0.2% | 2.9% |
| 1Y | 496.2% | -1.0% | 22.2% |
Return vs Industry: VERA exceeded the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: VERA exceeded the US Market which returned 21.9% over the past year.
Price Volatility
| VERA volatility | |
|---|---|
| VERA Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VERA's share price has been volatile over the past 3 months.
Volatility Over Time: VERA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 51 | Marshall Fordyce | veratx.com |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections.
Vera Therapeutics, Inc. Fundamentals Summary
| VERA fundamental statistics | |
|---|---|
| Market cap | US$2.16b |
| Earnings (TTM) | -US$95.99m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-22.5x
P/E RatioIs VERA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VERA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$95.99m |
| Earnings | -US$95.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.76 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 49.1% |
How did VERA perform over the long term?
See historical performance and comparison